相关实验视频
Updated: May 27, 2025

08:43
Investigating Intestinal Inflammation in DSS-induced Model of IBD
Published on: February 1, 2012
67.0K
在炎症性肠道疾病中的基因组脱乙酶:新的见解
Chunxiao Li1, Shaobo Gu2, Yihong Zhang3
1Department of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.
Therapeutic advances in gastroenterology
|February 18, 2025
概括
基因组脱乙酶 (HDACs) 在炎症性肠病 (IBD) 病原发生过程中至关重要. HDAC 抑制剂通过调节肠道炎症,显示出治疗IBD的潜力.
科学领域:
- 胃肠病学 胃肠病学
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 炎症性肠病 (IBD),包括性结肠炎和克罗恩病,涉及慢性肠道炎症.
- 肠胃炎症是一个重大的全球健康挑战,其发病率和发病率不断上升.
- 翻译后的修改,特别是基因素乙化,调节基因转录,并与IBD有关.
研究的目的:
- 为了总结基因素脱乙酶 (HDAC) 的类别和抑制剂 (HDACis).
- 分析HDAC抑制在缓解IBD中的作用.
- 探索HDACis在IBD治疗中的治疗和临床潜力.
主要方法:
- 对有关HDACs和IBD的现有文献进行审查和综合.
- 在肠道炎症中的HDAC功能背后的分子机制的分析.
- 在IBD模型中评估HDAC抑制剂的临床前和临床数据.
主要成果:
- HDACs通过脱乙 histone 和 nonhistone 蛋白质对IBD 病原体产生贡献.
- 抑制HDAC显示出缓解肠道炎症的潜力.
- 特定的HDAC抑制剂在IBD环境中表现出有前途的治疗效果.
结论:
- 在IBD的炎症途径中,HDACs是关键参与者.
- 抑制HDAC是一种有前途的治疗策略,用于治疗IBD.
- 为了有效治疗IBD,需要对HDACis进行进一步的临床研究.
相关概念视频
Inflammatory Bowel Disease II: Crohn's Disease
166
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
166
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
301
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
301
Inflammatory Bowel Disease I: Ulcerative Colitis
122
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
122
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
110
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
110
Inflammatory Bowel Disease IV: Pharmacological Management
95
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
95

